Related Pages for ZYDUSLIFE
- Option Chain
- Straddle OC
- Max Pain
- Put Call Ratio
- Option Analytics
- Call OI vs Put OI
- Strike Flow
- Call OI Chg vs Put OI Chg
- Call Vol vs Put Vol
- Buildup & Unwinding
- Vega Divergence
- Multi Strike OI
- Multi Straddle Analysis
- Price vs OI
- Time Series Table
- Time Series Multi Chart
- Volatility Skew
- Premium Decay
- IV - HV
- IV Intraday
- Future Chain
- Future Intraday Analysis
- Technical
- Financials
- Chart
- About
No results found.
ZYDUSLIFE
Related News - ZYDUSLIFE
Zydus: Jefferies on Zydus Maintains Buy with Target Price of ₹1,370 as 1QFY27 growth remained strong across India and international markets, US sales rose 5% QoQ on new launches, FY27 guidance was retained, and FTF launches and innovative products support growth beyond FY27 despite a 3% FY27 EPS cut.
12 Aug 2026 09:04 AM
Zydus: Jefferies on Zydus Maintains Buy with Target Price of ₹1,370 as 1QFY27 growth remained strong across India and international markets, US sales rose 5% QoQ on new launches, FY27 guidance was retained, and FTF launches and innovative products support growth beyond FY27 despite a 3% FY27 EPS cut.
Zydus: HSBC on Zydus Maintains Hold with Target Price of ₹1,100 as 1Q revenue growth was healthy but EBITDA margins missed estimates due to higher costs, while FY27 guidance was retained and branded-product initiatives are expected to build gradually, with saroglitazar magnesium FDA approval the next key catalyst.
12 Aug 2026 09:04 AM
Zydus: HSBC on Zydus Maintains Hold with Target Price of ₹1,100 as 1Q revenue growth was healthy but EBITDA margins missed estimates due to higher costs, while FY27 guidance was retained and branded-product initiatives are expected to build gradually, with saroglitazar magnesium FDA approval the next key catalyst.
Zydus: CLSA on Zydus Maintains Outperform with Target Price of ₹1,310 as 1QFY27 growth was healthy across ex-US segments, margins remained in line despite higher acquisition-related opex, FY27 double-digit revenue growth and 24% margin guidance were retained, and Assertio consolidation plus upcoming US launches support higher FY27–29 estimates.
12 Aug 2026 09:04 AM
Zydus: CLSA on Zydus Maintains Outperform with Target Price of ₹1,310 as 1QFY27 growth was healthy across ex-US segments, margins remained in line despite higher acquisition-related opex, FY27 double-digit revenue growth and 24% margin guidance were retained, and Assertio consolidation plus upcoming US launches support higher FY27–29 estimates.
Zydus: Citi on Zydus Maintains Sell with Target Price of ₹1,040 as EBITDA of ₹18.7bn beat estimates by 5% on strong 19.5% YoY India growth and resilient Mirabegron sales, while consolidated revenue grew 22% YoY with 12% from acquisitions and FY27 double-digit growth and ~24% EBITDA margin guidance were reiterated.
12 Aug 2026 09:04 AM
Zydus: Citi on Zydus Maintains Sell with Target Price of ₹1,040 as EBITDA of ₹18.7bn beat estimates by 5% on strong 19.5% YoY India growth and resilient Mirabegron sales, while consolidated revenue grew 22% YoY with 12% from acquisitions and FY27 double-digit growth and ~24% EBITDA margin guidance were reiterated.
Zydus Life: Assertio Holdings Projected to Add $15 Million to $20 Million Quarterly Starting Next Quarter. The Consumer Wellness Sector Expected to See Strong Double-Digit Growth for FY '27. Over Five Years, Branded Business Aims for EBITDA Margins of 28%-30% Plus.
12 Aug 2026 08:44 AM
Zydus Life: Assertio Holdings Projected to Add $15 Million to $20 Million Quarterly Starting Next Quarter. The Consumer Wellness Sector Expected to See Strong Double-Digit Growth for FY '27. Over Five Years, Branded Business Aims for EBITDA Margins of 28%-30% Plus.
Zydus Life: Keeps EBITDA Margin Target At Over 24% For FY '27 Despite Expected Higher Expenses For Saroglitazar In The Second Half Of The Year. Saroglitazar Is Set To Launch In FY '28 In The U.S., With Initial Years Focused On Investment And Expected Peak Sales Of $200M To $300M, Possibly Surpassing $400M.
12 Aug 2026 08:39 AM
Zydus Life: Keeps EBITDA Margin Target At Over 24% For FY '27 Despite Expected Higher Expenses For Saroglitazar In The Second Half Of The Year. Saroglitazar Is Set To Launch In FY '28 In The U.S., With Initial Years Focused On Investment And Expected Peak Sales Of $200M To $300M, Possibly Surpassing $400M.
Zydus Life: Company Expects Strong Double-Digit Revenue Growth For FY '27, With India Division Projected To Grow In The Mid-Teens, Surpassing Market By 3% To 5%. U.S. Business Anticipates Single-Digit Growth.
12 Aug 2026 08:39 AM
Zydus Life: Company Expects Strong Double-Digit Revenue Growth For FY '27, With India Division Projected To Grow In The Mid-Teens, Surpassing Market By 3% To 5%. U.S. Business Anticipates Single-Digit Growth.
Zydus Life: Expects Over Two-Thirds Of Revenue From Branded Portfolio, U.S. Business To Grow From 10% To 15% By Fiscal Year End
12 Aug 2026 08:43 AM
Zydus Life: Expects Over Two-Thirds Of Revenue From Branded Portfolio, U.S. Business To Grow From 10% To 15% By Fiscal Year End
ZYDUS LIFESCIENCES: Q1 CONS NET PROFIT 9.4B RUPEES VS 14.7B (YOY); EST 10B
11 Aug 2026 01:23 PM
ZYDUS LIFESCIENCES: Q1 CONS NET PROFIT 9.4B RUPEES VS 14.7B (YOY); EST 10B
ZYDUS LIFESCIENCES: Q1 REVENUE 80B RUPEES VS 66B (YOY)
11 Aug 2026 01:24 PM
ZYDUS LIFESCIENCES: Q1 REVENUE 80B RUPEES VS 66B (YOY)
ZYDUS LIFESCIENCES: Q1 EBITDA 19.3B RUPEES VS 20.88B (YOY) || Q1 EBITDA MARGIN 24.07% VS 31.8% (YOY)
11 Aug 2026 01:24 PM
ZYDUS LIFESCIENCES: Q1 EBITDA 19.3B RUPEES VS 20.88B (YOY) || Q1 EBITDA MARGIN 24.07% VS 31.8% (YOY)
Zydus Life: Receives USFDA Final Approval For Indocyanine Green Injection With 180-Day CGT Exclusivity
04 Aug 2026 03:10 PM
Zydus Life: Receives USFDA Final Approval For Indocyanine Green Injection With 180-Day CGT Exclusivity
Zydus Lifesciences: Company Gets USFDA EIR for Injectable Facility with VAI Classification.
01 Aug 2026 03:49 PM
Zydus Lifesciences: Company Gets USFDA EIR for Injectable Facility with VAI Classification.
Zydus Lifesciences: Co. Gets Green Light For Phase III Trial Of Desidustat For Sickle Cell Disease Patients In Partnership With ICMR; Phase II Trial Achieved Main Goals; Desidustat Has Orphan Drug Status From US FDA.
23 Jul 2026 10:05 AM
Zydus Lifesciences: Co. Gets Green Light For Phase III Trial Of Desidustat For Sickle Cell Disease Patients In Partnership With ICMR; Phase II Trial Achieved Main Goals; Desidustat Has Orphan Drug Status From US FDA.
Zydus Life: Co To Consider Q1 Results On August 11.
20 Jul 2026 12:54 PM
Zydus Life: Co To Consider Q1 Results On August 11.
Zydus Life: Co. Partners With Apollo Hospitals To Increase Availability Of SHIELD™ Multi-Cancer Detection Test In India
03 Jul 2026 12:17 PM
Zydus Life: Co. Partners With Apollo Hospitals To Increase Availability Of SHIELD™ Multi-Cancer Detection Test In India
Zydus Lifesciences: Co. Extends Closing Date For Acquisition Of API Business From Sterling Biotech Limited To September 30, 2026; Conditions Precedent Still Being Completed.
29 Jun 2026 02:37 PM
Zydus Lifesciences: Co. Extends Closing Date For Acquisition Of API Business From Sterling Biotech Limited To September 30, 2026; Conditions Precedent Still Being Completed.
Zydus Life: Forms Joint Venture With Sunshine Healthcare Lanka For 50% Stake In Zydus Sunshine Lifesciences With Investment Up To USD 5 Million.
26 Jun 2026 10:46 AM
Zydus Life: Forms Joint Venture With Sunshine Healthcare Lanka For 50% Stake In Zydus Sunshine Lifesciences With Investment Up To USD 5 Million.
Zydus Lifesciences: Company Gets Warning Letter From USFDA About Baddhi Facility; Letter Points Out Issues With Purified Talc Not Meeting USP Standards; Current Operations And Supplies Unaffected.
03 Jun 2026 10:29 AM
Zydus Lifesciences: Company Gets Warning Letter From USFDA About Baddhi Facility; Letter Points Out Issues With Purified Talc Not Meeting USP Standards; Current Operations And Supplies Unaffected.
Zydus Lifesciences: Company Gets US FDA Priority Review For Saroglitazar NDA To Treat PBC.
27 May 2026 05:33 PM
Zydus Lifesciences: Company Gets US FDA Priority Review For Saroglitazar NDA To Treat PBC.
